Deals Of The Week: GSK/UCB, Myriad/Panacos, Tragara/S*BIO
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Teva Adds To Biosimilars Capabilities Through Partnership With Lonza
Even as big pharma continues to express interest in developing follow-on biologics, Teva has taken a step toward solidifying a leadership position in the space. The world's largest generic company announced a tie-up Jan. 20 with the privately held Swiss contract manufacturing group Lonza
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
A mega merger combining Pfizer and Wyeth would create a behemoth with combined sales of over $70 billion, build Pfizer's experience base in biotech, give Pfizer the substantial vaccine business it has been searching for and create billions in cost savings opportunities
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
A mega merger combining Pfizer and Wyeth would create a behemoth with combined sales of over $70 billion, build Pfizer's experience base in biotech, give Pfizer the substantial vaccine business it has been searching for and create billions in cost savings opportunities